PON1
Serum paraoxonase/arylesterase 1
Also known as: ESA, PON, PON1_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P27169
- Gene
- PON1
- Ensembl
- ENSG00000005421
- Chromosome
- 7
- Canonical length
- 355 aa
- Protein class
- Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted secreted proteins, Transporters
- Secretome location
- Secreted to blood
- Quaternary structure
- Homodimer
OverviewNCBI Gene
This gene encodes a member of the paraoxonase family of enzymes and exhibits lactonase and ester hydrolase activity. Following synthesis in the kidney and liver, the enzyme is secreted into the circulation, where it binds to high density lipoprotein (HDL) particles and hydrolyzes thiolactones and xenobiotics, including paraoxon, a metabolite of the insecticide parathion. Polymorphisms in this gene may be associated with coronary artery disease and diabetic retinopathy. The gene is found in a cluster of three related paraoxonase genes on chromosome 7. [provided by RefSeq, Aug 2017]
Canonical amino-acid sequenceUniProt
355 residues, UniProt reviewed canonical sequence.
>P27169|PON1
1 MAKLIALTLL GMGLALFRNH QSSYQTRLNA LREVQPVELP NCNLVKGIET GSEDLEILPN
61 GLAFISSGLK YPGIKSFNPN SPGKILLMDL NEEDPTVLEL GITGSKFDVS SFNPHGISTF
121 TDEDNAMYLL VVNHPDAKST VELFKFQEEE KSLLHLKTIR HKLLPNLNDI VAVGPEHFYG
181 TNDHYFLDPY LQSWEMYLGL AWSYVVYYSP SEVRVVAEGF DFANGINISP DGKYVYIAEL
241 LAHKIHVYEK HANWTLTPLK SLDFNTLVDN ISVDPETGDL WVGCHPNGMK IFFYDSENPP
301 ASEVLRIQNI LTEEPKVTQV YAENGTVLQG STVASVYKGK LLIGTVFHKA LYCELLocalizationUniProt · AlphaFold · HPA
Whether an antibody against PON1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.24
- Highest tissue expression
- 498 nTPM
Expression across tissuesHPA
Tissue
- liver: 498 nTPM
- thymus: 4.7 nTPM
- adrenal gland: 4.3 nTPM
- gallbladder: 1 nTPM
- pituitary gland: 0.8 nTPM
- amygdala: 0.6 nTPM
Single-cell type
- hepatocytes: 582 nCPM
- retinal pigment epithelial cells: 85 nCPM
- cardiomyocytes: 26 nCPM
- cholangiocytes: 20 nCPM
- astrocytes: 13 nCPM
- tuft cells: 12 nCPM
Immune cell
- NK-cell: 0.1 nTPM
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
Brain region
- amygdala: 1.5 nTPM
- cerebellum: 1.5 nTPM
- cerebral cortex: 1.4 nTPM
- hypothalamus: 1.4 nTPM
- pons: 1.4 nTPM
- basal ganglia: 1.3 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about PON1.
Disease | AllUniProt
Conditions PON1 is implicated in, by any mechanism.
- Microvascular complications of diabetes 5 (MVCD5) MIM:612633
ReferencesPubMed · IEDB
Publications for PON1 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
2 publications
- Reduced paraoxonase1 activity is a risk for atherosclerosis in patients with systemic lupus erythematosus.
2007 · Ann N Y Acad Sci · RCR 1.4 · 49 citations - Serum Levels of Anti-PON1 and Anti-HDL Antibodies as Potential Biomarkers of Premature Atherosclerosis in Systemic Lupus Erythematosus.
2017 · Thromb Haemost · RCR 1.2 · 28 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.29
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.72
- DepMap mean gene effect
- -0.09
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- carboxylic acid catabolic process
- cholesterol metabolic process
- lactone catabolic process
- phosphatidylcholine metabolic process
- positive regulation of cholesterol efflux
- response to toxic substance
- organophosphate catabolic process
Molecular functions
- acyl-L-homoserine-lactone lactonohydrolase activity
- aryldialkylphosphatase activity
- arylesterase activity
- calcium ion binding
- phospholipid binding
- protein homodimerization activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of PON1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads PON1 as an antibody target. Whether an autoantibody or antibody against PON1 could matter depends on whether native PON1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
PON1 is annotated as secreted, so native PON1 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label PON1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...